Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros













Base de datos
Intervalo de año de publicación
1.
Environ Toxicol ; 39(4): 2439-2451, 2024 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-38205899

RESUMEN

Head-and-neck squamous cell carcinoma (HNSCC) patients often exhibit insensitivity to immunotherapy, leading to treatment failure. Identifying potential biomarkers that can predict prognosis and improve the efficacy of treatment is crucial. In this study, we aimed to identify necroptosis-related long noncoding RNAs (NRlncRNAs) as potential therapeutic targets to improve the prognosis of HNSCC patients. By exploring the Genotype-Tissue Expression Project (GTEx) and the Cancer Genome Atlas (TCGA) databases, we identified NRlncRNAs and developed a risk model comprising 17 NRlncRNAs to predict the prognosis of HNSCC patients and to classify patients into two clusters based on their expression levels. We conducted various analyses, such as the Kaplan-Meier analysis, GSEA and IC50 prediction, to evaluate the differences in sensitivity to immunotherapy between the two clusters. Our findings suggest that NRlncRNAs have potential as therapeutic targets for improving the prognosis of HNSCC patients, and that individualized treatment approaches based on NRlncRNA expression levels can improve the sensitivity of immunotherapy and overall treatment outcomes. This study highlights new perspectives within clinical cancer informatics and provides insight into potential therapeutic strategies for HNSCC patients.


Asunto(s)
Neoplasias de Cabeza y Cuello , ARN Largo no Codificante , Humanos , Carcinoma de Células Escamosas de Cabeza y Cuello/genética , Pronóstico , ARN Largo no Codificante/genética , Neoplasias de Cabeza y Cuello/genética , Neoplasias de Cabeza y Cuello/terapia , Aprendizaje Automático , Biomarcadores de Tumor/genética , Regulación Neoplásica de la Expresión Génica
2.
Altern Ther Health Med ; 29(8): 452-460, 2023 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-37652416

RESUMEN

Context: Ras-associated binding 35 (RAB35) is an oncogenic, guanosine triphosphate (GTP)ase that plays a role in cancer invasion, metastasis, and immune evasion. However, systematic and comprehensive research to identify the importance of RAB35 in various cancer types is still absent. Objective: The study intended to explore the potential value of RAB35 as a molecular biomarker. Design: The research team performed a genetic evaluation of RAB35. Setting: The study took place at the Second Affiliated Hospital of Wenzhou Medical University in Wenzhou, China. Outcome Measures: The research team assessed the expression of RAB35 in various tumor tissues and performed correlation analyses between RAB35 expression and prognosis, molecular subtypes, immunological subtypes, immune-associated cell infiltration, the tumor immune microenvironment, and drug sensitivity in pan-cancer. Results: RAB35 exhibited significant differential expression for 21 cancer types. It demonstrated high sensitivity and specificity in diagnosing eight cancer types, showed distinct expression patterns in various molecular subtypes for six cancer types, and found different immune subtypes for eight cancer types. The abnormal expression of RAB35 was significantly related to overall survival (OS) for nine cancer types, progress free interval (PFI) for five cancer types, and disease-specific survival (DSS) for five cancer types. Its abnormal expression was closely associated with the immune microenvironment and multiple immune cells. Furthermore, it was related to the drug sensitivity for various drugs and might be associated with chemotherapy resistance. Conclusions: RAB35 showed significant differential expression in various cancers and was significantly related to the prognosis of cancer patients, the immune microenvironment, multiple immune cells, drug sensitivity to various drugs, and chemotherapy resistance. It may serve as a potential biomarker and therapeutic target for cancer treatment.


Asunto(s)
Neoplasias , Humanos , Pronóstico , Neoplasias/diagnóstico , China , Biomarcadores , Microambiente Tumoral , Proteínas de Unión al GTP rab/genética
3.
Pol J Microbiol ; 70(2): 1-7, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34131429

RESUMEN

Rapid identification of microorganisms in urine is essential for patients with urinary tract infections (UTIs). Matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) has been proposed as a method for the direct identification of urinary pathogens. Our purpose was to compare centrifugation-based MALDI-TOF MS and short-term culture combined with MALDI-TOF MS for the direct identification of pathogens in urine specimens. We collected 965 urine specimens from patients with suspected UTIs, 211/965 isolates were identified as positive by conventional urine culture. Compared with the conventional method, the results of centrifugation-based MALDI-TOF MS were consistent in 159/211 cases (75.4%), of which 135/159 (84.9%) had scores ≥ 2.00; 182/211 cases (86.3%) were detected using short-term culture combined with MALDI-TOF MS, of which 153/182 (84.1%) had scores ≥ 2.00. There were no apparent differences among the three methods (p = 0.135). MALDI-TOF MS appears to accelerate the microbial identification speed in urine and saves at least 24 to 48 hours compared with the routine urine culture. Centrifugation-based MALDI-TOF MS is characterized by faster identification speed; however, it is substantially affected by the number of bacterial colonies. In contrast, short-term culture combined with MALDI-TOF MS has a higher detection rate but a relatively slow identification speed. Combining these characteristics, the two methods may be effective and reliable alternatives to traditional urine culture.


Asunto(s)
Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción , Infecciones Urinarias/microbiología , Bacterias/aislamiento & purificación , Técnicas Bacteriológicas , Femenino , Humanos , Masculino , Infecciones Urinarias/diagnóstico , Infecciones Urinarias/orina
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA